Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food effect of CKD-379 in healthy volunteers
NCT06652971Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Nov 2024
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-379 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve to the last measurable concentration and Maximum Plasma Concentration. Started Nov 2024; status: completed.
02
Drugs
CKD-379
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06652971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06652971.